TYK2 in Immune Responses and Treatment of Psoriasis
Lin Shang,* Jiali Cao,* Siqi Zhao, Jingya Zhang, Yanling He Department of Dermatology, Capital Medical University Affiliated Beijing Chaoyang Hospital, Beijing, People's Republic of China*These authors contributed equally to this workCorrespondence: Yanling He, Email hey...
Saved in:
Main Authors: | Shang L (Author), Cao J (Author), Zhao S (Author), Zhang J (Author), He Y (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
by: Robert Roskoski, Jr
Published: (2023) -
Mesenchymal stem cells alleviate psoriasis-like dermatitis in mice by inhibiting TYK2 phosphorylation
by: Lina LIANG, et al.
Published: (2022) -
A TYK2 Gene Mutation c.2395G>A Leads to TYK2 Deficiency: A Case Report and Literature Review
by: Peilin Wu, et al.
Published: (2020) -
Deucravacitinib, a TYK2 inhibitor, safety in psoriasis and psoriatic arthritis: What should a dermatologist know?
by: Inês Pereira Amaral, et al.
Published: (2023) -
Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
by: Ian M. Catlett, et al.
Published: (2024)